| Berzosertib studied in …STUDIED_INderived21 of 21show fewer |
|---|
| → studied in | NCT02595931Phase 1 · active not recruiting M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 21 trials list this drug (12 active) | — | — | Malignant Solid Neoplasm,Malignant Lung Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · 21 trials list this drug (12 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595892Phase 2 · active not recruiting Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 21 trials list this drug (12 active) | — | — | Ovarian Serous Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02567422Phase 1 · active not recruiting Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer · 21 trials list this drug (12 active) | — | — | Head and Neck Carcinoma of Unknown Primary,Head and Neck Squamous Cell Carcinoma,Laryngeal Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 21 trials list this drug (12 active) | — | — | Ovarian Endometrioid Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03517969Phase 2 · active not recruiting M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer · 21 trials list this drug (12 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03896503Phase 2 · active not recruiting Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs · 21 trials list this drug (12 active) | — | — | Extrapulmonary Small Cell Neuroendocrine Carcinoma,Lung Small Cell Carcinoma,Platinum-Resistant Lung Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052555Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer · 21 trials list this drug (12 active) | — | — | Breast Carcinoma,HER2-Negative Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641313Phase 2 · active not recruiting Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer · 21 trials list this drug (12 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826341Phase 1/Phase 2 · completed A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors · 21 trials list this drug (12 active) | — | — | Solid Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04266912Phase 1/Phase 2 · active not recruiting Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors · 21 trials list this drug (12 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02589522Phase 1 · active not recruiting Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors · 21 trials list this drug (12 active) | — | — | Lung Neuroendocrine Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802174Phase 1/Phase 2 · active not recruiting Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers · 21 trials list this drug (12 active) | — | — | Solid Neoplasm,Small Cell Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02567409Phase 2 · completed Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer · 21 trials list this drug (12 active) | — | — | Bladder Urothelial Carcinoma,Renal Pelvis and Ureter Urothelial Carcinoma,Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03309150Phase 1 · completed ATRi Transition Rollover Study · 21 trials list this drug (12 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05246111Phase 1 · completed Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) · 21 trials list this drug (12 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04768296Phase 2 · completed Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) · 21 trials list this drug (12 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641547Phase 1 · completed M6620 Plus Standard Treatment in Oesophageal and Other Cancer · 21 trials list this drug (12 active) | — | — | Solid Neoplasm,Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03718091Phase 2 · completed M6620 (VX-970) in Selected Solid Tumors · 21 trials list this drug (12 active) | — | — | Solid Neoplasm,Osteosarcoma,Leiomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704467Phase 1 · completed Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer · 21 trials list this drug (12 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02157792Phase 1 · completed M6620 First in Human Study · 21 trials list this drug (12 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |